AICAR vs Sermorelin

Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide; acadesine) is a non-peptide, cell-permeable nucleoside analog and prodrug that is phosphorylated intracellularly to its monophosphate form (ZMP), which mimics AMP to activate AMP-activated protein kinase (AMPK) — the primary cellular energy sensor — producing metabolic effects that partially phenocopy those of exercise and caloric restriction. AMPK activation by AICAR upregulates GLUT4 expression and glucose uptake, stimulates fatty acid oxidation, increases mitochondrial biogenesis via PGC-1alpha, and suppresses hepatic gluconeogenesis; a landmark 2008 preclinical study demonstrated that AICAR administration in sedentary mice increased running endurance and activated exercise-related gene expression programs without physical training, generating significant research interest in its potential as an exercise mimetic. The only published human clinical trial involved intravenous AICAR administration in patients with type 2 diabetes, where it reduced hepatic glucose output and inhibited whole-body lipolysis via AMPK, validating the pathway pharmacology in humans; the exercise-mimetic effects observed in rodents have not been replicated or evaluated in any human study, and no oral or injectable form has been assessed for human performance use in published research. AICAR is not a peptide and has no FDA approval; it is prohibited in sport by WADA, available only as a research chemical, and all performance-related interest derives from preclinical rodent data that has not been translated to human investigation; the IV metabolic effects in diabetic patients should not be extrapolated to an athletic or performance context.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism. The compound received FDA approval as Geref (Serono) for diagnosis and treatment of GH deficiency in children; approval was voluntarily withdrawn by the manufacturer in 2008 for commercial rather than safety reasons, leaving the underlying human evidence base intact, and compounded sermorelin has since been widely used off-label in adult anti-aging and hormone optimization practice. Sermorelin is currently available only through compounding pharmacies under prescriber supervision; it is not FDA-approved for any current indication, and its use in adults represents off-label prescribing outside the regulatory framework established by its original pediatric approval. Sermorelin is available through telehealth platforms and hormone optimization clinics across the United States and is dispensed by compounding pharmacies under licensed prescriber supervision. Patients searching for sermorelin providers near them or via telehealth can use the PeptideBase directory to browse verified clinics and telehealth platforms offering sermorelin by location. Sermorelin bodybuilding and anti-aging research contexts have driven its widespread compounded use in adults, though these applications are off-label and outside the original pediatric approval framework. Sermorelin near me: sermorelin is available through licensed anti-aging clinics, hormone health practices, and telehealth platforms that specialize in growth hormone axis support. Because sermorelin requires a prescription, access involves a clinical consultation — many providers now offer this remotely via telehealth, eliminating the need for in-person visits. For those searching for sermorelin providers near them, PeptideBase maintains a directory of verified clinics and telehealth platforms offering sermorelin protocols across the United States. Sermorelin and ipamorelin together: yes, sermorelin and ipamorelin are frequently combined in clinical research and compounded hormone optimization protocols. The two peptides act on different receptors — sermorelin on GHRH receptors (stimulating the GHRH pathway) and ipamorelin on ghrelin receptors (GHS-R1a) — and their mechanisms are complementary rather than redundant. Combining a GHRH analog like sermorelin with a GHRP like ipamorelin produces synergistic GH release, consistent with the well-established pharmacological principle that GHRH and GH secretagogues act additively at the pituitary. Ipamorelin is specifically valued in this combination for its selectivity — it stimulates GH without the cortisol or prolactin co-stimulation that characterizes less selective GHRPs such as GHRP-2 or GHRP-6. The sermorelin + ipamorelin combination (and its extension, the sermorelin + CJC-1295 + ipamorelin triple protocol) is among the most commonly prescribed compounded GH secretagogue regimens in anti-aging and hormone optimization practice. Providers offering combination GH secretagogue protocols are listed in the PeptideBase directory.